by Simon Clarke | Feb 21, 2025 | Blog
One of the greatest challenges in oncology research is developing preclinical cancer models that accurately reflect human disease. The industry has long relied on subcutaneous tumor models for early-stage drug testing. These models, which involve injecting cultured...
by Reaction Biology | Feb 11, 2025 | Blog
Adverse drug reactions (ADRs) remain one of the most significant challenges in drug development. Remarkably, around 75% of these ADRs are dose-dependent and can be predicted based on the pharmacological profiles of drug candidates. The only in vitro pharmacology assay...
by Reaction Biology | Oct 1, 2024 | Blog
In the early 1990s, the discovery of promising anti-cancer agents from large-scale 60-cell line screens created an overwhelming demand for testing in traditional xenograft models. The sheer number of compounds needing evaluation far exceeded the resources available....
by Reaction Biology | Aug 29, 2024 | Blog
Reaction Biology’s Assay Formats HotSpot™ Kinase Screen Using the Gold Standard Radiometric Assay The HotSpot™ Kinase Screen uses a radiometric assay format, which directly measures kinase activity by detecting the incorporation of radioactive phosphate into the...
by Reaction Biology | Aug 26, 2024 | Blog
Testing the efficacy of lead compounds in animal models is a crucial step in preclinical drug development. Researchers have many in vivo tumor models to choose from, but selecting the right one involves considering factors such as cost, time, and technical expertise....
by John Hewitt | Aug 13, 2024 | Blog
The ATP binding site of kinases represents both a golden opportunity and a formidable challenge for drug discovery teams. This well-defined pocket serves as the docking site for potent small-molecule inhibitors, making it an attractive target for drug development....
